Mechanistic studies revealed that exportin 1 inhibition downregulated SOX2.227 These findings, coupled with the clinical availability of selinexor, which is FDA-approved for treatment-refractory hematological malignancies, position exportin 1 as a compelling target to prevent plasticity in these aggressive tumors. This evidence concerns the gene XPO1 and hematologic disorder.